Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg slashes Videndum target price, sticks with 'hold'

(Sharecast News) - Berenberg has maintained a 'hold' rating on Videndum but slashed its target price for the stock by almost a half, saying it is awaiting a clear turnaround in performance from the content creation solutions provider. The broker said it has updated its forecasts to reflect "evolving industry dynamics across Videndum's main customer categories and the group's updated guidance".

As a result, its target for the shares has been cut from 140p to just 80p, with the stock having tanked more than 70% over the past year on the back of a number of profit warnings and reports of a slower-than-expected recovery in the media and film markets.

"While we recognise that management has taken steps to improve the business and improve liquidity, a number of changes will take time to take full effect, hampering earnings recovery," Berenberg said in a research note on Friday.

Nevertheless, the broker noted a "slowly improving picture" at Videndum, which sells both hardware (like camera supports and stabilisers, video monitors, lighting and audio equipment) and services to customers in the content creation industries.

"2025 has started softly, but is improving steadily month on month. Videndum has done a lot of work on the industry dynamics and trends as part of the current refinancing process, and so expects flat revenue year on year with low single-digit operating margins and a high H2 weighting," Berenberg said.

Despite the 'hold' stance, the broker acknowledged that Videndum shares are "inexpensive", trading at an enterprise value-to-EBITDA multiple of 7x.

The stock was up nearly 3% at 77.8p by 1014 BST.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.